Cantor Fitzgerald Reaffirms Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “hold” rating reiterated by investment analysts at Cantor Fitzgerald in a note issued to investors on Monday. They currently have a $6.50 price target on the stock. Cantor Fitzgerald’s price target suggests a potential downside of 11.80% from the company’s current price.
Assembly Biosciences (NASDAQ:ASMB) opened at 7.41 on Monday. Assembly Biosciences has a 52-week low of $4.25 and a 52-week high of $23.45. The stock’s 50-day moving average is $7.0 and its 200-day moving average is $7.63. The company’s market cap is $34.7 million.
Assembly Biosciences Inc, formerly Ventrus Biosciences, Inc is a development-stage specialty pharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.